Thyroid cancer: no benefit for prophylactic central neck dissection

  • Front Endocrinol

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Prophylactic central neck dissection (pCND) failed to reduce recurrence rates in patients undergoing total thyroidectomy for clinically node-negative papillary thyroid cancer (PTC).

Why this matters

  • pCND has unclear benefit and a high complication rate in this patient population.

Key results

  • Propensity-score matching generated patient groups without significant differences in age (P=.417), sex (P=.732), tumor size (P=.177), extrathyroidal extension (P=.777), lymphovascular invasion (P=.175), perineural invasion (P=.600), bilaterality (P=.758), multiplicity (P=.308), TNM stage (P=.120), or subtype (P=1.0).
  • Patients who underwent pCND and those who did not had similar recurrence rates (2.96% vs 1.48%; P=.684), time to recurrence (71.5 vs 49.5 months; P=.355), and 5-year recurrence-free survival (97.2% vs 98.1%; P=.571).

Study design

  • 477 patients with clinically node-negative PTC measuring
  • Propensity-matched cohorts of 135 patients who underwent pCND vs 135 who did not.
  • Funding: None disclosed.

Limitations

  • Retrospective study design.
  • 88.5% of tumors were

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit